Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor

doi:10.1016/S0960-894X(02)00518-8

Bioorganic & Medicinal Chemistry Letters

Volume 12, Issue 18, 16 September 2002, Pages 2583-2586

https://doi.org/10.1016/S0960-894X(02)00518-8 Get rights and content

Abstract

Potent and selective ligands for the human EP3 prostanoid receptor are described. Biaryl compounds bearing a tethered ortho substituted acidic moiety were identified as potent EP3 antagonists based on the SAR described herein. The binding affinity of key compounds on all eight human prostanoid receptors is reported.

Potent and selective ligands for the human EP₃ prostanoid receptor are described. Biaryl compounds bearing a tethered ortho substituted acidic moiety were identified as potent EP₃ antagonists based on the SAR described herein. The binding affinity of key compounds on all eight human prostanoid receptors is reported.

Section snippets

Acknowledgements

The authors would like to thank Dr Daniel Dubé for proofreading this manuscript.

References (12)

Y. Sugimoto et al.
Prog. Lipid. Res.
(2000)
S. Narumiya et al.
Physiol. Rev.
(1999)
R.A. Coleman et al.
Pharmacol. Rev.
(1994)
W.T. Ashton et al.
J. Med. Chem.
(1994)
R.W. Friesen et al.
Tetrahedron Lett.
(1993)
M. Abramovitz et al.
Biochim. Biophys. Acta
(2000)
A. Kiryiama et al.
Br. J. Pharmacol.
(1997)
Y. Shimazaki et al.
Bioorg. Med. Chem.
(2000)

There are more references available in the full text version of this article.

Cited by (39)

Structure-activity relationship studies of novel 3-oxazolidinedione-6- naphthyl-2-pyridinones as potent and orally bioavailable EP<inf>3</inf> receptor antagonists
2011, Bioorganic and Medicinal Chemistry Letters
Multiple regions of the 3-oxazolidinedione-6-naphthyl-pyridinone series identified via high throughput screening were explored. SAR studies of these regions including the left-hand side oxazolidinedione moiety, α-substituent on the oxazolidinedione ring, central pyridinone core, and substituents on the central pyridinone core led to the discovery of potent EP₃ receptor antagonists such as compound 29 which possesses outstanding rat pharmacokinetic properties. Synthesis and SAR of these novel compounds and DMPK properties of representative compounds are discussed.
3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP <inf>3</inf> receptor antagonists
2010, Bioorganic and Medicinal Chemistry Letters
Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: Implications for anti-restenotic potential
2010, European Journal of Pharmacology
Prostacyclin analogues have the potential to be effective agents in a new generation of drug-eluting stents by virtue of prostanoid IP receptor mediated anti-proliferative effects on smooth muscle cells. However, prostanoid IP receptor mediated vessel relaxation is reduced at elevated analogue concentrations. The mechanisms underlying this loss of activity are unclear, and its influence on the anti-proliferative potential of these compounds remains to be determined. A classical organ bath approach was used to examine the functional response of the rabbit iliac artery to the prostacyclin analogues, AFP-07 and cicaprost. Selective receptor antagonists for prostanoid IP (RO-1138452), EP₁ (SC-51322) and EP₃ (L-798106) receptors were used to characterise the receptors involved. The effects of these agents on proliferation ([³H]-thymidine incorporation) of rabbit iliac artery smooth muscle cells stimulated by foetal calf serum were then studied. AFP-07 gave a bell-shaped log concentration–response curve consisting of prostanoid IP receptor mediated relaxation followed by reversal at higher concentrations. SC-51322 and L-798106 potentiated this relaxation, although only L-798106 completely removed the contractile element. The prostanoid EP₃ receptor agonist, sulprostone, produced constriction, which was attenuated by L-798106. RO-1138452 blocked the inhibitory action of AFP-07 and cicaprost on proliferation, implicating an involvement of prostanoid IP receptors. L-798106 had no effect on the anti-proliferative effect of cicaprost, but reduced the effect of AFP-07. Non-selective activation of prostanoid EP₃ receptors (and possibly prostanoid EP₁ receptors) compromises the relaxant activity of prostacyclin analogues, although it does not reduce the anti-proliferative capacity of these compounds in the model studied.
Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists
2010, Bioorganic and Medicinal Chemistry Letters
A series of novel N-acylsulfonamide analogs were synthesized and evaluated for their binding affinity and antagonist activity for the EP3 receptor subtype. Representative compounds were also evaluated for their inhibitory effect on PGE₂-induced uterine contraction in pregnant rats. Among those tested, a series of N-acylbenzenesulfonamide analogs were found to be more potent than the corresponding carboxylic acid analogs in both the in vitro and in vivo evaluations. The structure activity relationships (SAR) are also discussed.
3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: Discovery and exploration of the carboxyamide side chain
2010, Bioorganic and Medicinal Chemistry
A series of 3-(2-aminocarbonyl-4-phenoxymethylphenyl)propanoic acid analogs were synthesized and evaluated for their EP3 antagonist activity in the presence of additive serum albumin. Several compounds were biologically evaluated for their in vivo efficacy with respect to the PGE₂-induced uterine contraction in pregnant rats as well as their pharmacokinetics. The discovery process of these potent and selective EP3 antagonists and their structure activity relationship are also presented.
Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists
2009, Bioorganic and Medicinal Chemistry
A series of acrylic acids and their structurally related compounds were evaluated for their binding affinity to four EP receptor subtypes (EP1-4). Starting from the initial hit 3, which was discovered in our in-house library, compounds 4 and 5 were identified as new chemical leads as candidates for further optimization towards a selective EP3 receptor antagonist. The identification process of these compounds and their pharmacokinetic profiles are presented.

View all citing articles on Scopus

View full text

Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor

Abstract

Section snippets

Acknowledgements

Prog. Lipid. Res.

Physiol. Rev.

Pharmacol. Rev.

J. Med. Chem.

Tetrahedron Lett.

Biochim. Biophys. Acta

Br. J. Pharmacol.

Bioorg. Med. Chem.

Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP₃ Prostanoid Receptor